๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase I surrogate endpoint study of SU6668 in patients with solid tumors

โœ Scribed by Henry Q. Xiong; Roy Herbst; Silvana C. Faria; Catherine Scholz; Darren Davis; Edward F. Jackson; Timothy Madden; David McConkey; Marshall Hicks; Kenneth Hess; Chusilp (Arthur) Charnsangavej; James L. Abbruzzese

Book ID
111579927
Publisher
Springer US
Year
2004
Tongue
English
Weight
82 KB
Volume
22
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase I study of gemcitabine and docet
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
โœ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 70 KB ๐Ÿ‘ 2 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and